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Although endovascular aneurysm repair (EVAR) of intact 
infrarenal abdominal aortic aneurysms (AAA) has been 
associated with a reduction in early mortality and morbidity 
as compared with open repair, the benefits of an endovascu-
lar strategy do not appear to translate to the treatment of 
ruptured aneurysms. Two randomized trials have demon-
strated no difference in 30-day mortality when comparing 
open and endovascular repair of ruptured AAA.1,2
The Nellix endovascular aneurysm sealing (EVAS) sys-
tem (Endologix, Irvine, CA, USA) offers a new approach to 
the endovascular treatment of AAA, achieving aneurysm 
exclusion by sealing the aneurysm sac. Each Nellix system 
consists of two identical catheter-based devices with a 
10-mm flow lumen being created by two balloon-expandable 
polytetrafluoroethylene–covered cobalt–chromium stents 
(Figure 1). The stents are mounted on balloons for deploy-
ment and are surrounded by polyurethane endobags. While 
conventional endografts have a proximal and distal attach-
ment zone for fixation, the EVAS device fixes the two stents 
within the aneurysm sac using the endobags, which are 
filled with a polyethylene glycol (PEG)-based hydrogel that 
conforms to the aneurysm flow lumen and solidifies within 
minutes of delivery, providing fixation and seal at the aortic 
neck and iliac arteries. Endobag filling is performed under 
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Abstract
Purpose: To assess the feasibility and report preliminary results of ruptured abdominal aortic aneurysm (rAAA) repair 
with endovascular aneurysm sealing (EVAS), a novel therapeutic alternative whose feasibility has not been established in 
rAAAs due to the unknown effects of the rupture site on the ability to achieve sealing. Case Report: Between December 
2013 and April 2014, 5 patients (median age 71 years, range 57–90; 3 men) with rAAAs were treated with the Nellix EVAS 
system at a single institution. Median aneurysm diameter was 70 mm (range 67–91). Aneurysm morphology in 4 of the 5 
patients was noncompliant with instructions for use (IFU) for both EVAS and standard stent-grafts; the remaining patient 
was outside the IFU for standard stent-grafts but treated with EVAS under standard IFU for the Nellix system. Median 
Hardman index was 2 (range 0–3). Two patients died of multiorgan failure after re-laparotomy and intraoperative cardiac 
arrest, respectively. Among survivors, all devices were patent with no signs of endoleak or failed aneurysm sac sealing at 
6 months (median follow-up 9.2 months). Conclusion: EVAS for the management of infrarenal rAAAs appears feasible. 
The use of EVAS in emergency repairs may broaden the selection criteria of the current endovascular strategy to include 
patients with more complex aneurysm morphology.
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pressure monitoring, which allows the polymer to be 
instilled to a pressure of 180 to 220 mm Hg, which will seal 
the aneurysm. One of the potential difficulties in treating 
ruptured aneurysms with EVAS is whether the aneurysm 
rupture site will preclude the development of an adequate 
pressure during polymer fill to enable aneurysm sealing. 
Moreover, there is a theoretical risk of increasing the size of 
tear at the site of rupture.
Adverse aneurysm morphology remains a key challenge 
for conventional EVAR, and many devices are currently 
used outside the manufacturer’s instructions for use (IFU), 
according to clinical need. The IFU accompanying the 
Nellix device suggest that an endovascular strategy may be 
feasible in a greater number of patients with a broader range 
of aortic morphology.3–5 We present our initial experience 
using EVAS in the treatment of patients with a ruptured 
infrarenal aneurysm.
Case Series
Prior to December 2013, 50 patients with AAA were treated 
with Nellix in an elective setting at our institute. All sur-
geons treating patients in the cases presented here had expe-
rience in ≥10 elective cases using the Nellix device. 
Eligibility for EVAS in infrarenal ruptured AAA was estab-
lished based on morphological suitability and the decision 
of clinicians with audited experience in emergency EVAR. 
Ruptured AAAs with morphology within the IFU for stan-
dard EVAR devices were not considered for EVAS.
Between December 2013 and March 2014, 5 patients 
(median age 71 years, range 57–90; 3 men) with ruptured 
infrarenal AAAs were treated with EVAS. All patients were 
conscious and lucid during the consent process and the nov-
elty of this treatment option was explained to each before 
they provided written informed consent prior to aneurysm 
repair. Baseline characteristics, aneurysm morphology, and 
procedural details for each of the patients are displayed in 
Table 1. Aneurysm morphology in 4 of the 5 patients was 
noncompliant with the IFU for both Nellix and standard 
EVAR devices; the remaining patient was outside the IFU 
for standard EVAR devices but treated with Nellix under 
standard IFU for the Nellix system (Table 1).
Prospectively collected baseline clinical and morphol-
ogy data included the Hardman index6,7 and aneurysm neck 
length, diameter, and angulation (Table 1). The decision to 
perform EVAS under local or general anesthesia was made 
according to clinical circumstance, with local anesthesia 
preferred if feasible. Centerline measurements on computed 
tomographic angiography (CTA) reconstructions were used 
to calculate aneurysm length and volume prior to surgery to 
allow stent sizing and thawing of the appropriate volume of 
polymer.
Local anesthesia was used in 4 cases, but 1 patient 
required general anesthesia (Table 1). Bilateral percutane-
ous access via the femoral arteries with ultrasound guidance 
was preferred, with Proglide closure devices (Abbott 
Vascular, Abbott Park, IL, USA) deployed at both access 
sites. However, a unilateral cutdown was required in 2 
patients where percutaneous closure application failed.
After visualization of the lowest renal artery under angi-
ographic control, a calibrated pigtail catheter was used to 
confirm the length to the bifurcation and subsequently the 
length of the devices needed. The median stent length was 
160 mm (range 140–180) on the left side and 170 mm 
(range 140–180) on the right (Table 1).
The Nellix devices were inserted through the femoral 
access sites bilaterally and advanced over wires into posi-
tion at the renal ostia. After retracting the covering sheaths, 
the stent-grafts were deployed by simultaneous inflation 
of the balloons within the stents to 7 atm (Figure 2A). The 
endobag was inflated first with a saline “pre-fill” to con-
firm the required polymer volume then with the aqueous 
PEG-based polymer (Figure 2B). Endobag fill pressures 
did not exceed 230 mm Hg. Five minutes following poly-
mer curing, endobag pressures were checked again, and 
the delivery devices were removed. A secondary fill was 
performed in all patients. The stents were routinely postdi-
lated using a 10-×40-mm angioplasty balloon (Cook 
Medical, Bloomington, IN, USA) inflated to 7 atm. 
Completion angiography was used to demonstrate suc-
cessful sealing of the ruptured aneurysm with bilaterally 
patent stent-grafts and iliac arteries. If the angle between 
the Nellix stent-graft and the iliac vessel wall was too 
large or ended at a curvature within the iliac artery, addi-
tional uncovered self-expanding stents (Cook Medical) 
were applied. In these 5 cases, a single adjunctive bare 
metal stent was deployed at the distal end of the EVAS 
device (iliac arteries) in 2 patients. A median of 3 units of 
blood was required during surgery, which lasted a median 
85 minutes (interquartile range 75–90). Median intensive 
care unit stay was 3 days (range 0–6) and median hospital 
stay was 8 days (range 0–40) (Table 1).
Postoperative surveillance consisted of a predischarge 
duplex scan and CTA if postoperative renal function 
Figure 1. Nellix endoprosthesis. Illustration courtesy of 
Endologix.
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permitted; CTA was repeated at 6 months after discharge, 
and the duplex scan was done at both 3 and 6 months in an 
outpatient setting (Figure 3B). The surveillance require-
ments of EVAS remain to be defined,8,9 and this protocol 
differs from the duplex-only surveillance conducted follow-
ing ruptured AAA repair with a conventional endograft.
Among the 5 patients treated with this device, 2 died. 
The first patient became hemodynamically unstable prior to 
surgery. Hemodynamic parameters deteriorated further fol-
lowing anesthetic induction; an endovascular sealing sys-
tem was deployed, but the patient experienced cardiac arrest 
on the operating table and died. The other patient had hemo-
dynamic instability on postoperative day 2; an emergency 
laparotomy was performed, and bleeding was observed 
from the aneurysm sac, assumed to result from a proximal 
type I endoleak. The device was explanted, and an aortobi-
femoral repair was performed. A colonic resection was sub-
sequently performed for bowel ischemia on day 4 after 
EVAS. The patient developed multiorgan failure and died 6 
days after initial surgery.
Postoperative CTA performed in the 3 surviving patients 
demonstrated no endoleak and no limb occlusions. Median 
follow-up of surviving patients was 9.3 months; at 3 and 6 
months, all 3 devices were patent on duplex ultrasound and 
CTA, with no evidence of endoleak or insufficient aneu-
rysm sac sealing among the survivors.
Discussion
This report summarizes a preliminary clinical experience 
with the Nellix device for ruptured AAA repair. In contrast 
to EVAR devices, the Nellix system uses a sac-anchoring 
endoprosthesis for aneurysm exclusion. The small numbers 
in this report do not permit comparison with existing EVAR 
devices or open repair; however, they do support the feasi-
bility of EVAS for ruptured infrarenal aneurysm repair in 
Table 1. Baseline Characteristics, Aneurysm Morphology, and Procedural/ Postoperative Details.
Patients
Variables 1 2 3 4 5
Baseline characteristics
 Age, y 90 57 70 85 70
 Sex Male Female Female Male Male
 Blood pressure, mm Hg 91/62 99/65 105/55 80/55 145/99
 Hemoglobin, g/dL 10.7 9.7 7.6 13.9 11.2
 Creatinine, µM/L 104 604 225 144 119
 Acute myocardial ischemia on ECG Yes No Yes Yes No
 Loss of consciousness No No No No No
 Hardman index (0–5) 2 1 3 2 0
Aneurysm morphology
 Maximum aneurysm diameter, mm 68 70 75 91 67
 Neck length, mm 31 154 24 19 22
 Neck diameter, mm 23 19 24 34 33
 Infrarenal (β) neck angulation, deg 62 147 58 94 56
 Suprarenal (α) neck angulation, deg 76 145 49 67 53
 Maximum flow lumen diameter, mm 46 56 52 60 42
Procedural/postoperative details
 Ineligibility for open repair Comorbidity Previous abdominal 
surgery and peritonitis
Comorbidity Comorbidity Comorbidity
 ASA grade 5 4 5 5 5
 Blood required during surgery, units 3 3 2 6 0
 Local anesthesia Yes Yes Yes No Yes
 Procedure duration, min 90 75 85 90 65
 Nellix stent length left/right, mm 160/160 170/170 140/140 180/180 160/170
 Adjunctive stent-graft Yes No No Yes No
 Polymer volume, mL 120 135 120 200 100
 Percutaneous groin access closure, n 1 2 1 2 2
 Intensive care unit stay, d 3 4 6 0 1
 Hospital stay, d 16 40 6 0 8
Abbreviations: ASA, American Society of Anesthesiologists; ECG, electrocardiogram.
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cases with morphological suitability, for example, those 
with a maximum aortic flow lumen diameter of ≤60 mm. 
Nellix devices were successfully deployed without peripro-
cedural events in 3 of 5 patients. EVAS may therefore pro-
vide an alternative to open or conventional endovascular 
repair of ruptured AAA.
The Nellix system offers several potential advantages 
over a conventional endografts for ruptured aneurysm 
repair. First, EVAS has been shown to be applicable to a 
wider range of aortic morphology (Figure 4) than currently 
available EVAR devices.3–5 The potential to use EVAS to 
treat patients who are noncompliant with the IFU of exist-
ing aortic stent-grafts is attractive in light of the higher 
incidence of sac expansion observed in patients treated by 
EVAR outside the IFU.10,11 The IFU for the Nellix devices 
specify that they are not suitable for patients with small or 
large common iliac arteries (<8 or >35 mm, respectively) or 
those with a large patent flow lumen (>60 mm) within the 
aneurysm sac.3–5
The inventory of devices required for EVAS is less com-
pared with that for conventional endografts, as the only siz-
ing variation in the Nellix system is related to stent length. 
Preoperative sizing is therefore straightforward, involving 
the selection of only a suitable length of device, which may 
be of benefit in an emergency setting.12 The avoidance of 
contralateral limb cannulation in EVAS may reduce the 
overall procedure duration in certain cases. The Nellix sys-
tem also provides an option for early hemostasis through 
endobag inflation with saline, while maintaining limb per-
fusion. A final advantage is the avoidance of type II endo-
leaks with aneurysm sac sealing.
The potential disadvantages of the EVAS technique 
for ruptured aneurysm repair include a risk of enlarging 
a rupture or tearing the aorta with the pressure used to fill 
the endobags. In addition, there is the potential for fail-
ure to seal a ruptured aneurysm due to an inability to 
generate the required pressure within the ruptured aneu-
rysm sac. It is suspected that one patient in this cohort 
developed a type I endoleak that was not obvious on sur-
veillance CT performed on postoperative day 1. Despite 
satisfactory appearances on the CTA, the patient was 
returned to surgery for laparotomy during a period of 
hemodynamic instability, where bleeding was observed 
Figure 3. (A) Preoperative axial computed tomography 
angiography (CTA) scan of the aorta showing the hematoma 
surrounding the aneurysm, indicative of rupture. (B) The 
postoperative axial CTA with the endobags and stent-grafts 
within the aneurysm.
Figure 4. Preoperative computed tomographic angiography 
reconstruction showing hostile neck anatomy amenable to 
treatment with endovascular aneurysm sealing (EVAS).
Figure 2. (A) The Nellix stents deployed within a ruptured 
infrarenal aneurysm, with the endobags not insufflated. (B) The 
Nellix device fully deployed with hemostatic control of the 
rupture and perfusion to both limbs.
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from the aneurysm sac. As such, it would be reasonable 
to assume that a type I endoleak was responsible for 
reperfusion of the sac. On retrospective review of the 
postoperative images, there was opportunity to increase 
the proximal sealing zone by deploying the stent closer 
to the renal ostia. The detection of endoleaks with CTA in 
the early postoperative period after EVAS does pose a 
challenge due to the opacification of the polymer-filled 
endobags. The optimal imaging modality for surveil-
lance at various postoperative periods remains to be 
determined.
Although preliminary, the current report of 5 patients 
provides the most substantial information to date about the 
feasibility of EVAS in ruptured aneurysm repair. The tech-
nique appears feasible, but clearly a refined protocol for the 
use of EVAS in ruptured AAA is required with consider-
ation of the need for saline pre-fill and target polymer fill 
pressures in addition to identifying specific morphological 
parameters that predict success or failure.
In each patient there were several reasons for not select-
ing open repair, including previous laparotomy or peritoni-
tis associated with continuous ambulatory peritoneal 
dialysis. In other cases, the patients were considered high 
risk for general anesthesia based on comorbidity, and a 
local anesthetic alternative was considered optimal. 
However, open repair should not be forgotten as a treatment 
option for ruptured AAA. An important consideration with 
any new device is durability, and longer follow-up is needed 
in a cohort of patients treated with EVAS to compare this 
modality with existing endovascular techniques.
Conclusion
Endovascular aneurysm sealing appears feasible for the man-
agement of ruptured aneurysms, with acceptable short-term 
outcome, albeit in a small series of patients. The application 
of EVAS devices for ruptured aneurysm repair may broaden 
the selection criteria of the current endovascular strategy to 
include patients with complex aneurysm morphology.13–15
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